[43] Wakefield D, Di Girolamo N, Thurau S, Wildner G, McCluskey P . 2013: Scleritis: challenges in immunopathogenesis and treatment. Discov Med, 16(88):153-157.

[44] Jabs DA, Rosenbaum JT. 2001. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol, 131(5):679

[45] Goyal A, Goyal K, Merola JF. 2015. Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists. Am J Clin Dermatol, 16(3):179-195.

[46] Gabardi S, Tullius SG, Krenzien F.2015. Understanding alterations in drug handling with aging: a focus on the pharmacokinetics of maintenance immunosuppressants in the elderly. Current opinion in organ transplantation, 20(4):424-430.

[47] Kempen JH, Daniel E, Gangaputra S, Dreger K, Jabs DA, Kacmaz RO, Pujari SS, Anzaar F, Foster CS, Helzlsouer KJ. 2011 : Methods for identifying long-term adverse effects of treatment in patients with eye diseases: The Systemic Immunosuppressive Therapy

[48] Eye Diseases (SITE) Cohort Study. 2008. Ophthalmic epidemiology, 15(1):47-55